Store-operated Ca2+ entry (SOCE) mediated by calcium release-activated calcium (CRAC) channels contributes to calcium signaling. The resulting intracellular calcium increases activate calcineurin, which in turn activates immune transcription factor nuclear factor of activated T cells (NFAT). Microglia contain CRAC channels, but little is known whether these channels play a role in acute brain insults. We studied a novel CRAC channel inhibitor to explore the therapeutic potential of this compound in microglia-mediated injury. Cultured microglial BV2 cells were activated by Toll-like receptor agonists or IFNγ. Some cultures were treated with a novel CRAC channel inhibitor (CM-EX-137). Western blots revealed the presence of CRAC channel proteins STIM1 and Orai1 in BV2 cells. CM-EX-137 decreased nitric oxide (NO) release and inducible nitric oxide synthase (iNOS) expression in activated microglia and reduced agonist-induced intracellular calcium accumulation in microglia, while suppressing inflammatory transcription factors nuclear factor kappa B (NF-κB) and nuclear factor of activated T cells (NFAT). Male C57/BL6 mice exposed to experimental brain trauma and treated with CM-EX-137 had decreased lesion size, brain hemorrhage, and improved neurological deficits with decreased microglial activation, iNOS and Orai1 and STIM1 levels. We suggest a novel anti-inflammatory approach for managing acute brain injury. Our observations also shed light on new calcium signaling pathways not described previously in brain injury models.
Get full access to this article
View all access options for this article.
References
1.
IadecolaC. and AnratherJ. (2011). The immunology of stroke: from mechanisms to translation. Nat. Med. 17, 796–808.
2.
CorpsK.N., RothT.L., and McGavernD.B. (2015). Inflammation and neuroprotection in traumatic brain injury. JAMA Neurol. 72, 355–362.
3.
KraftR. (2015). STIM and ORAI proteins in the nervous system. Channels (Austin) 9, 245–252.
4.
BeckA., PennerR., and FleigA. (2008). Lipopolysaccharide-induced down-regulation of Ca2+ release-activated Ca2+ currents (I CRAC) but not Ca2+-activated TRPM4-like currents (I CAN) in cultured mouse microglial cells. J. Physiol. 586, 427–439.
5.
OhanaL., NewellE.W., StanleyE.F., and SchlichterL.C. (2009). The Ca2+ release-activated Ca2+ current (I(CRAC)) mediates store-operated Ca2+ entry in rat microglia. Channels (Austin) 3, 129–139.
6.
RoosJ., DiGregorioP.J., YerominA.V., OhlsenK., LioudynoM., ZhangS., SafrinaO., KozakJ.A., WagnerS.L., CahalanM.D., VelicelebiG., and StaudermanK.A. (2005). STIM1, an essential and conserved component of store-operated Ca2+ channel function. J. Cell Biol. 169, 435–445.
7.
ZhangS.L., YuY., RoosJ., KozakJ.A., DeerinckT.J., EllismanM.H., StaudermanK.A., and CahalanM.D. (2005). STIM1 is a Ca2+ sensor that activates CRAC channels and migrates from the Ca2+ store to the plasma membrane. Nature, 437, 902–905.
8.
ShimA.H., Tirado-LeeL., and PrakriyaM. (2015). Structural and functional mechanisms of CRAC channel regulation. J. Mol. Biol. 427, 77–93.
9.
FurmanJ.L. and NorrisC.M. (2014). Calcineurin and glial signaling: neuroinflammation and beyond. J. Neuroinflammation, 11, 158.
10.
ChoT.H., AguettazP., CampuzanoO., Charriaut-MarlangueC., RiouA., BerthezeneY., NighoghossianN., OvizeM., WiartM., and ChauveauF. (2013). Pre- and post-treatment with cyclosporine A in a rat model of transient focal cerebral ischaemia with multimodal MRI screening. Int. J. Stroke, 8, 669–674.
11.
KurodaS., JanelidzeS., and SiesjoB.K. (1999). The immunosuppressants cyclosporin A and FK506 equally ameliorate brain damage due to 30-min middle cerebral artery occlusion in hyperglycemic rats. Brain Res. 835, 148–153.
12.
OsmanM.M., LulicD., GloverL., StahlC.E., LauT., van LoverenH., and BorlonganC.V. (2011). Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application. Neuropeptides, 45, 359–368.
13.
FuruichiY., MaedaM., MatsuokaN., MutohS., and YanagiharaT. (2007). Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: comparison with tissue plasminogen activator. Exp. Neurol. 204, 138–146.
14.
MacleodM.R., O'CollinsT., HorkyL.L., HowellsD.W., and DonnanG.A. (2005). Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J. Cereb. Blood Flow Metab. 25, 713–721.
15.
MarmarouC.R. and PovlishockJ.T. (2006). Administration of the immunophilin ligand FK506 differentially attenuates neurofilament compaction and impaired axonal transport in injured axons following diffuse traumatic brain injury. Exp. Neurol. 197, 353–362.
16.
GoldB.G., VodaJ., YuX., McKeonG., and BourdetteD.N. (2004). FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis. J. Neurosci. Res. 77, 367–377.
17.
SingletonR.H., StoneJ.R., OkonkwoD.O., PellicaneA.J., and PovlishockJ.T. (2001). The immunophilin ligand FK506 attenuates axonal injury in an impact-acceleration model of traumatic brain injury. J. Neurotrauma, 18, 607–614.
18.
BechsteinW.O. (2000). Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl. Int. 13, 313–326.
19.
MalvezziP. and RostaingL. (2015). The safety of calcineurin inhibitors for kidney-transplant patients. Expert Opin. Drug Saf. 14, 1531–1546.
20.
KacimiR., GiffardR.G., and YenariM.A. (2011). Endotoxin-activated microglia injure brain derived endothelial cells via NF-kappaB, JAK-STAT and JNK stress kinase pathways. J. Inflamm. (Lond), 8, 7.
21.
KacimiR. and YenariM.A. (2015). Pharmacologic heat shock protein 70 induction confers cytoprotection against inflammation in gliovascular cells. Glia, 63, 1200–1212.
22.
ZhengZ., KimJ.Y., MaH., LeeJ.E., and YenariM.A. (2008). Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke. J. Cereb. Blood Flow Metab. 28, 53–63.
23.
HanH.S., QiaoY., KarabiyikogluM., GiffardR.G., and YenariM.A. (2002). Influence of mild hypothermia on inducible nitric oxide synthase expression and reactive nitrogen production in experimental stroke and inflammation. J. Neurosci. 22, 3921–3928.
24.
KimJ.Y., KimN., YenariM.A., and ChangW. (2013). Hypothermia and pharmacological regimens that prevent overexpression and overactivity of the extracellular calcium-sensing receptor protect neurons against traumatic brain injury. J. Neurotrauma, 30, 1170–1176.
25.
DengH., HanH.S., ChengD., SunG.H., and YenariM.A. (2003). Mild hypothermia inhibits inflammation after experimental stroke and brain inflammation. Stroke, 34, 2495–2501.
26.
d'AvilaJ.C., LamT.I., BinghamD, ShiJ., WonS.J., KauppinenT.M., MassaS., LiuJ., and SwansonR.A. (2012). Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor. J. Neuroinflammation, 9, 31.
27.
KimN., KimJ.Y., and YenariM.A. (2015). Pharmacological induction of the 70-kDa heat shock protein protects against brain injury. Neuroscience, 284, 912–919.
28.
TangX.N., BermanA.E., SwansonR.A., and YenariM.A. (2010). Digitally quantifying cerebral hemorrhage using Photoshop and Image J. J. Neurosci. Methods, 190, 240–243.
29.
WangG.J., DengH.Y., MaierC.M., SunG.H., and YenariM.A. (2002). Mild hypothermia reduces ICAM-1 expression, neutrophil infiltration and microglia/monocyte accumulation following experimental stroke. Neuroscience, 114, 1081–1090.
30.
HoffmannA., KannO., OhlemeyerC., HanischU.K., and KettenmannH. (2003). Elevation of basal intracellular calcium as a central element in the activation of brain macrophages (microglia): suppression of receptor-evoked calcium signaling and control of release function. J. Neurosci. 23, 4410–4419.
VigM., BeckA., BillingsleyJ.M., LisA., ParvezS., PeineltC., KoomoaD.L., SoboloffJ., GillD.L., FleigA., KinetJ.P., and PennerR. (2006). CRACM1 multimers form the ion-selective pore of the CRAC channel. Curr. Biol. 16, 2073–2079.
33.
LiouJ., KimM.L., HeoW.D., JonesJ.T., MyersJ.W., FerrellJ.E.Jr., and MeyerT. (2005). STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx. Curr. Biol. 15, 1235–1241.
34.
CahalanM.D., ZhangS.L., YerominA.V., OhlsenK., RoosJ., and StaudermanK.A. (2007). Molecular basis of the CRAC channel. Cell Calcium, 42, 133–144.
35.
FeskeS., GwackY., PrakriyaM., SrikanthS., PuppelS.H., TanasaB., HoganP.G., LewisR.S., DalyM., and RaoA. (2006). A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature, 441, 179–185.
36.
PrakriyaM., FeskeS., GwackY., SrikanthS., RaoA., and HoganP.G. (2006). Orai1 is an essential pore subunit of the CRAC channel. Nature, 443, 230–233.
37.
RaoA., LuoC., and HoganP.G. (1997). Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15, 707–747.
38.
EylensteinA., SchmidtS., GuS., YangW., SchmidE., SchmidtE.M., AlesutanI., SzteynK., RegelI., ShumilinamE., and LangF. (2012). Transcription factor NF-κB regulates expression of pore-forming Ca2+ channel unit, Orai1, and its activator, STIM1, to control Ca2+ entry and affect cellular functions. J. Biol. Chem. 287, 2719–2730.
39.
Berna-ErroA., BraunA., KraftR., KleinschnitzC., SchuhmannM.K., StegnerD., WultschT., EilersJ., MeuthS.G., StollG., and NieswandtB. (2009). STIM2 regulates capacitive Ca2+ entry in neurons and plays a key role in hypoxic neuronal cell death. Sci. Signal., 2, ra67.
40.
MaJ., McCarlC.A., KhalilS., LuthyK., and FeskeS. (2010). T-cell-specific deletion of STIM1 and STIM2 protects mice from EAE by impairing the effector functions of Th1 and Th17 cells. Eur. J. Immunol. 40, 3028–3042.
41.
RaoW., ZhangL., PengC., HuiH., WangK., SuN., WangL., DaiS.H., YangY.F., ChenT., LuoP., and FeiZ. (2015). Downregulation of STIM2 improves neuronal survival after traumatic brain injury by alleviating calcium overload and mitochondrial dysfunction. Biochim. Biophys. Acta, 1852, 2402–2413.
42.
HouP.F., LiuZ.H., LiN., ChengW.J., and GuoS.W. (2015). Knockdown of STIM1 improves neuronal survival after traumatic neuronal injury through regulating mGluR1-dependent Ca(2+) signaling in mouse cortical neurons. Cell Mol. Neurobiol. 35, 283–292.
43.
HeoD.K., LimH.M., NamJ.H., LeeM.G., and KimJ.Y. (2015). Regulation of phagocytosis and cytokine secretion by store-operated calcium entry in primary isolated murine microglia. Cell Signal. 27, 177–186.
44.
SaganovaK., GalikJ., BlaskoJ., KorimovaA., RacekovaE., and VanickyI. (2012). Immunosuppressant FK506: focusing on neuroprotective effects following brain and spinal cord injury. Life Sci. 91, 77–82.
45.
ServaisH., OrtizA., DevuystO., DenamurS., TulkensP.M., and Mingeot-LeclercqM.P. (2008). Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis, 13, 11–32.
46.
ChristiansU., GottschalkS., MiljusJ., HainzC., BenetL.Z., LeibfritzD., and SerkovaN. (2004). Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br. J. Pharmacol. 143, 388–396.
47.
SerkovaN.J., ChristiansU., and BenetL.Z. (2004). Biochemical mechanisms of cyclosporine neurotoxicity. Mol. Interv. 4, 97–107.
48.
DixonC.E., BramlettH.M., DietrichW.D., ShearD.A., YanH.Q., Deng-BryantY., MondelloS., WangK.K., HayesR.L., EmpeyP.E., PovlishockJ.T., TortellaF.C., and KochanekP.M. (2016). Cyclosporine treatment in traumatic brain injury: operation brain trauma therapy. J. Neurotrauma, 33, 553–566.
49.
SiekierkaJ.J. and SigalN.H. (1992). FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. Curr. Opin. Immunol. 4, 548–552.
FuruichiY., NotoT., LiJ.Y., OkuT., IshiyeM., MoriguchiA., AramoriI., MatsuokaN., MutohS., and YanagiharaT. (2004). Multiple modes of action of tacrolimus (FK506) for neuroprotective action on ischemic damage after transient focal cerebral ischemia in rats. Brain Res. 1014, 120–130.
52.
KaminskaB., Gaweda-WalerychK., and ZawadzkaM. (2004). Molecular mechanisms of neuroprotective action of immunosuppressants—facts and hypotheses. J. Cell Mol. Med. 8, 45–58.
53.
ChiuC.C., LiaoY.E., YangL.Y., WangJ.Y., TweedieD., KarnatiH.K., GreigN.H., and WangJ.Y. (2016). Neuroinflammation in animal models of traumatic brain injury. J. Neurosci. Methods, 272, 38–49.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
